F9 and hemophilia B: In the hemophilia B field, a recent study [63] exploiting a Cas9-based approach demonstrated the possibility to correct disease-causing point mutations in endogenous F9. Through the delivery of Cas9 nuclease and donor DNA as naked DNA molecules, to liver tissue by hydrodynamic injection, single-stranded DNA oligonucleotides (ssODNs) and plasmid donor-mediated HDR efficiency of 0.56% and 1.55% were respectively attained.